Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ
Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-Ⅱ
Proportion of patients with excellent defined as mRS score ≤ 1 at 90 days.
To test the hypothesis that rhTNK-tPA is non-inferior to alteplase in thrombolysis treatment
 when administered within 4.5 hours of ischemic stroke onset.
Inclusion Criteria:

 -  Age ≥18 years old, no gender limitation;

 -  The time from onset to treatment was < 4.5h;The time at which symptoms begin is
 defined as "the time at which they finally appear normal";

 -  The clinical diagnosis was ischemic stroke (the diagnosis followed the Chinese
 Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018);

 -  MRS before onset was 0-1 points

 -  Baseline NIHSS 5-25(both included);

 -  Informed consent from the patient or surrogate.

 Exclusion Criteria:

 -  Intended to proceed endovascular treatment;

 -  NIHSS consciousness score >2;

 -  Allergy to tenecteplase or alteplase;

 -  Past history of intracranial hemorrhage ;

 -  A history of severe head trauma or stroke within 3 months;

 -  A history of intracranial or spinal surgery within 3 months;

 -  A history of gastrointestinal or urinary bleeding within 3 weeks;

 -  2 weeks of major surgery;

 -  Arterial puncture was performed at the hemostasis site that was not easily compressed
 within 1 week;

 -  Intracranial tumors (except neuroectodermal tumors, such as meningiomas), large
 intracranial aneurysms;

 -  Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular
 hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);

 -  Active visceral bleeding;

 -  Aortic arch dissection was found;

 -  After active antihypertensive treatment, hypertension is still not under control:
 systolic blood pressure ≥180 mm Hg, or diastolic blood pressure ≥100 mm Hg;

 -  Propensity for acute bleeding, including platelet counts of less than 100×109/ L or
 otherwise;

 -  Blood glucose <2.8 mmol/L or >22.22 mmol/L;

 -  Oral warfarin anticoagulant with INR>1.7 or PT>15 s;

 -  Heparin treatment was received within 24 h;

 -  Thrombin inhibitors or factor Xa inhibitors were used within 48 h;

 -  Head CT or MRI showed a large infarction (infarcted area > 1/3 of the middle cerebral
 artery);

 -  Subjects who are unable or unwilling to cooperate due to hemiplegia (Todd's palsy)
 after epileptic seizure or other neurological/psychiatric disorders;

 -  Pregnant women, lactating women, or subjects who do not agree to use effective
 contraception during the trial;

 -  Participation in other clinical trials within 3 months prior to screening;

 -  Unsuitability or participation in this study as judged by the Investigator may result
 in subjects being exposed to greater risk.